Showing 4431-4440 of 5910 results for "".
- Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-completes-dosing-in-oasis-phase-12a-clinical-trial-of-cls-ax-in-wet-amd-patients/2480989/Clearside Biomedical announced today completion of dosing in Cohorts 3 and 4 of OASIS, its phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a US-based, multicen
- Schwind Eye-Tech Solutions Receives Funding for Laser Surgery Projecthttps://modernod.com/news/schwind-eye-tech-solutions-receives-funding-for-laser-surgery-project/2480987/Schwind eye-tech-solutions announced funding for a new research project aimed at developing an ophthalmic laser system with ultra-short laser pulses[1]. Schwind is planning initial investment in basic research of more than 1.6 million euros, of which around 52% is funding from
- AbbVie and iSTAR Medical Announce Strategic Alliancehttps://modernod.com/news/abbvie-and-istar-medical-announce-strategic-alliance/2480980/AbbVie and iSTAR Medical announced a strategic transaction to further develop and commercialize iSTAR Medical’s MINIject device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. The deal gives AbbVie the exclusive right to acquire iST
- Report: Diagnosed Cases of AMD in the Seven Major Markets Expected to Grow Over Next 10 Yearshttps://modernod.com/news/report-diagnosed-cases-of-amd-in-the-seven-major-markets-expected-to-grow-over-next-10-years/2480979/Diagnosed prevalent cases of age-related macular degeneration (AMD) in the seven major markets combined is expected to increase from 33.66 million cases in 2021 to 40.32 million in 2031, at an annual growth rate (AGR) of 1.98%, according to GlobalData. Of the seven major mark
- Verana Health Presents Geographic Atrophy and Diabetic Macular Edema Research at ASRS 2022https://modernod.com/news/verana-health-presents-geographic-atrophy-and-diabetic-macular-edema-research-at-asrs-2022/2480976/Verana Health delivered two podium presentations at the American Society of Retina Specialists annual meeting in New York City on July 15. The research findings were generated through analysis of Ophthalmology Qdata, real-world data resulting from the curation
- Apellis Announces FDA Acceptance and Priority Review of the NDA for Pegcetacoplan for the Treatment of Geographic Atrophyhttps://modernod.com/news/apellis-announces-fda-acceptance-and-priority-review-of-the-nda-for-pegcetacoplan-for-the-treatment-of-geographic-atrophy/2480973/Apellis Pharmaceuticals announced that the FDA has accepted and granted Priority Review designation for the intravitreal pegcetacoplan new drug application (NDA). Pegcetacoplan is an investigational, targeted C3 therapy for the treatment of geographic atrophy (GA) secondary to age-relat
- Bausch + Lomb and Novaliq Submit New Drug Application for Investigational NOV03 for Dry Eye Disease Associated with MGDhttps://modernod.com/news/bausch-lomb-and-novaliq-submission-new-drug-application-for-investigational-nov03-for-dry-eye-disease-associated-with-mgd/2480972/Bausch + Lomb and Novaliq announced the submission of a new drug application (NDA) at the end of June to FDA seeking approval for NOV03 (perfluorohexyloctane), an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease (DED) associated
- New App Allows Surgeons to Search for FDA Approved IOLshttps://modernod.com/news/new-app-allows-surgeons-to-search-for-fda-approved-iols/2480969/Matt Hirabayashi, MD, of eyeflymd.com, and Gurpal Virdi, MD, of Eyelabs.ai, have developed an app called “eyeSpace,” which is designed to allow surgeons and trainees to
- American Academy of Optometry Launches Nationwide Search for New CEOhttps://modernod.com/news/american-academy-of-optometry-launches-nationwide-search-for-new-ceo/2480968/The American Academy of Optometry (AAO) has formed a search committee to identify candidates for the position of Chief Executive Officer. Current Chief Financial Officer (CFO)/Deputy CEO Richard Jones will serve as Interim Chief Executive Officer throughout the search. Mr. Jones has more than 20
- After Building New Plant and Signing on with AbbVie, Regenxbio Enters Commercial Phasehttps://modernod.com/news/after-building-new-plant-and-signing-on-with-abbvie-regenxbio-enters-commercial-phase/2480967/An article in FiercePharma details the expansion plans of Regenxbio—with its new building as tangible evidence of its arrival as a burgeoning commercial busines